PRODUTOS TÓPICOS PARA USO EM PELE INTACTA OU PELE DANIFICADA PARA USO COSMÉTICO E / OU COMO UM DISPOSITIVO MÉDICO

A cosmetic product with sonicated hyaluronic acid and fibroblast-secreted growth factors addresses skin aging by regenerating both skin layers, effectively reducing wrinkles and scars without invasive treatments.

BR112025024352A2Pending Publication Date: 2026-11-10BLAST RES SRL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025024352
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2024-05-09
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Current cosmetic treatments for skin aging and wrinkles are temporary, invasive, and often cause side effects, while topical formulations fail to adequately replenish collagen and elastin, leading to repeated treatments and skin irritation.

Method used

A cosmetic product containing a concentrate of sonicated hyaluronic acid (80-1200 kDa) and growth factors/cytokines secreted by fibroblast cell culture, formulated to penetrate and regenerate both the epidermis and dermis, promoting tissue repair and collagen synthesis.

Benefits of technology

The product effectively reduces wrinkles, scars, and skin irritations by enhancing skin hydration, elasticity, and tissue regeneration, providing a long-lasting solution without invasive procedures.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention concerns the cosmetic field, and in particular relates to a cosmetic product and to its uses. Specifically, the invention relates to a cosmetic product comprising a concentrate and sonicated hyaluronic acid, having a mean molecular weight in the range from 100kDa to 500kDa; wherein said concentrate comprises at least one growth factor and at least one cytokine. The invention further relates to the use of the cosmetic product for promoting tissue regeneration, for improving skin texture, for reducing skin wrinkles and scars and for reducing skin irritation and blemishing.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 47 “TOPICAL PRODUCTS FOR USE ON INTACT OR DAMAGED SKIN FOR COSMETIC USE AND / OR AS A MEDICAL DEVICE” FIELD OF THE INVENTION

[0001] The present invention relates to the field of cosmetics and, in particular, refers to a cosmetic product and its uses.

[0002] Specifically, the invention relates to a cosmetic product comprising a concentrate of sonicated hyaluronic acid having an average molecular weight in the range of 80 kDa to 1200 kDa; wherein said concentrate comprises at least one growth factor and at least one cytokine.

[0003] The invention also relates to the use of the cosmetic product to promote tissue regeneration, to improve skin texture, to reduce wrinkles and skin scars, as well as to reduce skin irritations and imperfections. STATE OF THE ART

[0004] Currently, there is no cure for skin aging, and treatments for skin showing signs of aging and / or wrinkles are temporary and have disadvantages and side effects.

[0005] The loss of skin strength and thickness is due to the deterioration of collagen and elastic proteins present in the dermal layers, which can result in fine lines and wrinkles.

[0006] There are many surgical methods available for treating facial wrinkles, such as facelifts, laser surgery, chemical peels, and injectable therapies. However, surgical methods need to be repeated over time and can result in complications. Treatments do not Petition 870250106689, dated 11 / 21 / 2025, page 7 / 63 2 / 47 Invasive methods include topical formulations; however, none of these methods completely eliminate wrinkles and require multiple, often expensive, treatments. Some topical formulations can irritate the skin, causing scarring reactions, but do not adequately replenish the proteins necessary for the treatment and / or prevention of age-related imperfections.

[0007] Cell culture medium is vital for the growth and function of cells in vitro, providing nutrients and growth factors such as essential amino acids, salts, vitamins, minerals, trace elements, sugars, lipids and nucleosides.

[0008] Many cell culture media have been formulated to allow the growth of a wide range of cell types and experimental applications. Cells are said to be incubated in a cell culture medium as soon as they come into contact with it.

[0009] A cell culture medium incubated with cells is known as conditioned medium. Conditioned medium differs from the original medium by containing various cellular metabolites and secreted proteins, in addition to a variety of original medium components. Examples of metabolites and proteins secreted by cells into the medium during growth include growth factors, inflammatory mediators, and other extracellular proteins, which may have beneficial biological effects on epidermal remodeling and have aroused increasing interest in the field of cosmetics.

[0010] However, there is a growing need and importance for more effective cosmetic products for Petition 870250106689, dated 11 / 21 / 2025, page 8 / 63 3 / 47 Treatment and / or prevention of skin imperfections caused by aging and environmental factors.

[0011] Therefore, the objective of the present invention is the development of advantageous skin care products that act on the dermal layers and not just on the surface of the skin. SUMMARY OF THE INVENTION

[0012] In fact, without adhering to any theory, the inventors surprisingly discovered that the problem can be solved with a cosmetic product comprising: - a concentrate comprising at least one growth factor and at least one cytokine, secreted by a fibroblast cell culture, and - Sonicated hyaluronic acid, having an average molecular weight in the range of 80 kDa to 1200 kDa; whereby the said concentrate is obtainable by a process comprising the following steps: a. Provide a fibroblast cell culture in a culture medium; b. To stimulate the release of at least one growth factor and at least one cytokine into the cell culture medium from step a. in order to obtain a conditioned cell culture medium; c. Isolate the conditioned cell culture medium from step b. of the cell culture, to obtain an isolated conditioned cell culture medium; d. Concentrate the conditioned cell culture medium isolated from step c. to obtain a concentrate. Petition 870250106689, dated 11 / 21 / 2025, page 9 / 63 4 / 47

[0013] The cosmetic product may be, for example, a topical formulation, active in the treatment and / or prevention of skin damage, wrinkles and / or other defects caused by aging and environmental factors.

[0014] The cosmetic product may be formulated to prevent, reduce and / or eliminate wrinkles, expression lines, scars and other skin conditions associated with aging, as a complement to or alternative to the use of surgery, injectables, silicone or other products.

[0015] In a second aspect, this invention provides for the use of the cosmetic product to promote tissue regeneration.

[0016] In a third aspect, the cosmetic product according to the invention can be used to improve skin texture.

[0017] In a fourth aspect, the invention relates to the use of the cosmetic product to reduce wrinkles on the skin.

[0018] In a fifth aspect, the invention relates to the use of the cosmetic product to reduce scars.

[0019] Sixthly, the use of the cosmetic product to reduce skin irritation and imperfections is described here. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] The features and advantages of the present invention will become apparent from the detailed description given below, from the examples provided by way of illustration and not limitation, and from the attached figures 1 to 8.

[0021] Figure 1: Electrophoresis gel for protein content analysis. CCM samples were applied to acrylamide gel (in a 4-12% gradient): at position 4 Petition 870250106689, dated 11 / 21 / 2025, page 10 / 63 At position 5 / 47 we found batch 1 and at position 7, batch 2. Subsequently, the gel was stained with silver, which allowed us to highlight the proteins in brown.

[0022] Figure 2 shows an illustration of the co-culture assay in the Traswell system, as described in Example 6.

[0023] Figure 3: RT-PCR results. The bars correspond to the gene expression level of HMGB1 and type 1 collagen in fibroblasts: fibroblast population 1 (left), fibroblast population 2 (right), and the central bar corresponds to the fibroblast population 1 cultured in the transwell system, which is in indirect contact with the fibroblast population 2. The left and right bars represent the control cells, and the central bar represents the treated cells. A. HMGB1, 48 h B. Type 1 collagen, 8 days.

[0024] Figure 4: Gel electrophoresis of HA samples after staining with Stain-All. This dye allows the identification of hyaluronic acid in blue.

[0025] Figure 5: Gaussian distribution of sonicated HA fragments, as described in Example 7. A. Cream and B. Serum

[0026] Figure 6: Stability test of HA. Agarose gel electrophoresis and staining with Stain All. This dye allows the identification of hyaluronic acid in blue.

[0027] Figure 7: Fibroblast Scratch Test. Images acquired at 100x magnification and graph of the results obtained in: A. T0: fibroblasts immediately after injury; B. T24: natural cell migration after 24 hours without skin treatment; and C. T24: cell migration after 24 hours with treatment. Petition 870250106689, dated 11 / 21 / 2025, page 11 / 63 6 / 47 of the skin with the cosmetic product of the invention during the 24-hour incubation period. D: graph of the percentage of the migration area after 24 hours.

[0028] Figure 8: Scratch test on keratinocytes. Images acquired at 100x magnification and graph of the results obtained over 24 hours of incubation. Results obtained in: A. T0: keratinocytes immediately after injury, B. T24: natural cell migration after 24 hours if the skin is not treated, C. T24: cell migration after 24 hours if the skin is treated with the cosmetic product of the invention, and D. graph of the percentage of the migration area after 24 hours. DETAILED DESCRIPTION OF THE INVENTION

[0029] The present invention relates to a cosmetic product comprising: - a concentrate comprising at least one growth factor and at least one cytokine, secreted by a fibroblast cell culture, and - Sonicated hyaluronic acid, having an average molecular weight in the range of 80 kDa to 1200 kDa; whereby the said concentrate is obtainable by a process comprising the following steps: a. Provide a fibroblast cell culture in a culture medium; b. To stimulate the release of at least one growth factor and at least one cytokine into the cell culture medium from step a. in order to obtain a conditioned cell culture medium; Petition 870250106689, dated 11 / 21 / 2025, page 12 / 63 7 / 47 c. Isolate the conditioned cell culture medium from step b. of the cell culture, to obtain an isolated conditioned cell culture medium; d. Concentrate the conditioned cell culture medium isolated from step c. to obtain a concentrate.

[0030] The resulting cosmetic product contains a mixture of growth factors and cytokines secreted by fibroblasts, along with matrix proteins.

[0031] As used herein, the term concentrated or Concentrated Conditioned Medium or CCM refers to the product obtained after step d. of the process of the present invention. Example 4 describes a possible way of obtaining CCM by Tangential Flow Filtration.

[0032] As used herein, the term sonicated hyaluronic acid or HA or sonicated sodium hyaluronate refers to hyaluronic acid that has undergone the sonication process, as exemplified in Example 7, and which comprises hyaluronic acid fragments of different sizes. Depending on the product formulation, HA may be present only as sonicated HA or as a mixture of sonicated HA and Low molecular weight non-sonicated HA. For example, a product may contain only sonicated hyaluronic acid (HA) with a molecular weight in the range of 1200 kDa to 80 kDa, or a mixture of sonicated hyaluronic acid (in the range of 1200 kDa to 80 kDa) with the addition of low molecular weight hyaluronic acid (LMWH), with a molecular weight in the range of 1000 to 400 kDa, which has not been sonicated. Typically, the HA in the products of the invention has a size ranging from 1200 kDa to 80 kDa in varying amounts, for example, in the following quantities: Petition 870250106689, dated 11 / 21 / 2025, page 13 / 63 8 / 47 - 5 to 20%, preferably around 9% of fragments of 1200 to 800 kDa; - 30 to 40%, preferably around 32 to 33% of fragments of 800 to 400 kDa; - 30 to 40%, preferably around 34 to 35% of fragments of 400 to 200 kDa; and - 5 to 20%, preferably around 15% of fragments of 200 to 80 kDa.

[0033] One of the most important characteristics of HA is its molecular weight. Molecular weight determines the properties of HA and is essential for determining the permeability of the molecule in the skin.

[0034] Morphologically, if the polymer is short, it unfolds more easily and has an advantage in terms of movement (medium / low molecular weight HA). The longer the polymer, the more voluminous and slower it is (high molecular weight HA).

[0035] High molecular weight hyaluronic acid (HA) (above 500 kDa) is not absorbed by the skin, exerting its action on the epidermis. In fact, when applied to the skin's surface, high molecular weight HA acts by forming a hydrated viscoelastic film. This film is permeable to air, allowing cutaneous respiration to remain unobstructed, while the film retains moisture on the skin's surface. Moreover, the main advantage of high molecular weight hyaluronic acid is its good water retention capacity; thus, once applied to the skin, HA functions primarily as a film-forming polymer: it reduces water evaporation, with an occlusive action. Furthermore, the film-forming action Petition 870250106689, dated 11 / 21 / 2025, page 14 / 63 9 / 47 of HA allows, through mechanical means, the reduction of evaporation from the skin and limits interaction with environmental factors such as temperature, humidity, and UV radiation. In this way, the protective barrier of HA improves skin hydration and promotes local healing of superficial wounds.

[0036] Medium / low molecular weight fatty acids are able to perform their function in the deeper layers of the skin, reaching the dermis. Because they are smaller, they encounter fewer obstacles when crossing the epidermis and perform their functions in the dermis.

[0037] HA is a fundamental component of the extracellular matrix of the dermis, as it stimulates the proliferation and migration of fibroblasts, endothelial cells, and keratinocytes, in addition to promoting neoangiogenesis. Thanks to its action in the deeper layers of the skin, HA is able to maintain a high hydration rate in the deep epidermis, improving skin tone and elasticity.

[0038] The contribution of medium / low molecular weight HA is essential to assist in the physiological maintenance of the extracellular matrix in the dermis.

[0039] In order for HA to act on both skin levels, part of the HA in the product of the invention is fragmented by means of sonication.

[0040] The “cosmetic product”, as used herein, refers to a product comprising two ingredients: hyaluronic acid (HA in the forms of HA-LMW and a mixture of HA-LMW and sonicated HA, depending on the product formulation) and CCM. Petition 870250106689, dated 11 / 21 / 2025, page 15 / 63 10 / 47

[0041] Preferably, the cosmetic product of the present invention may also comprise excipients suitable for the final formulation.

[0042] The two main components: CCM and HA work in synergy to improve your individual potential.

[0043] Without adhering to any theory: - CCM acts as a stabilizing agent for HA. The interaction of HA with CCM proteins allows them to cross the epidermal barrier, thus enhancing their action in the dermis as well.

[0044] The combined action of CCM and HA in the cosmetic product promotes the natural regeneration of the epidermis and dermis.

[0045] The concentrate is free of animal proteins and is obtained from expanded fibroblast cultures in the process of the invention.

[0046] In one embodiment, the cosmetic product of the present invention can be obtained by a process in which step b. of stimulating the release of at least one growth factor and at least one cytokine in the cell culture medium of said process is performed by subjecting the fibroblast cell culture to a nutrient deprivation step.

[0047] In a preferred aspect, at the end of the process, in step d., the conditioned concentrate can be sterilely filtered.

[0048] In another embodiment, the cosmetic product of the present invention can be obtained by a process in which fibroblasts are isolated from a tissue sample, the tissue preferably being chosen from the group consisting of skin and umbilical cord. Petition 870250106689, dated 11 / 21 / 2025, page 16 / 63 11 / 47

[0049] For the isolation of cells from the chosen tissue, the skin biopsy undergoes digestion. As described in Example 1, tissues can be treated with a neutral protease, washed, and subsequently digested with collagenase. The resulting cell suspension is then seeded and incubated in complete medium.

[0050] In another embodiment, therefore, the cosmetic product of the present invention can be obtained by a process in which fibroblasts are isolated from the tissue sample by digestion with a protease and, subsequently, with a collagenase.

[0051] In another embodiment, the cosmetic product of the present invention can be obtained by a process in which the concentrate comprises a mixture of growth factors, cytokines and matrix proteins.

[0052] The quantification of CCM protein content can be performed using the bicinchoninic acid (BCA) protein assay, also known as the Smith assay, as shown in Example 5.

[0053] In another embodiment, the cosmetic product of the present invention can be obtained by a process in which the concentrate comprises one or more growth factors, for example, those listed in Table 1, which lists the main components of the fibroblast secretome. The cosmetic product of the present invention can be obtained by a process in which said concentrate comprises one or more growth factors selected from the group comprising: Vascular Endothelial Growth Factor (VEGF), Transforming Growth Factor β (TGF-β) and Growth Factors of Petition 870250106689, dated 11 / 21 / 2025, page 17 / 63 12 / 47 Fibroblast Growth Factors (FGFs), Platelet-Derived Growth Factor (PDGF), Granulocyte Colony-Stimulating Factor (GCSF), Keratinocyte Growth Factor (KGF), Transforming Growth Factor Beta 3 (TGF-β3), Nerve Growth Factor Beta (NGF-β), Sirtuin 1 (SIRT1), Sirtuin 2 (SIRT2), Tissue Inhibitor for Metalloproteinase 1 (TIMP-1), Macrophage Colony-Stimulating Factor 1 (M-CSF or CSF1), Stem Cell Factor (SCF), Insulin-like Growth Factor (IGF-1), Insulin-like Growth Factor 2 (IGF2), Interleukin 10 (IL-10), and Hepatocyte Growth Factor (HGF). Petition 870250106689, dated 11 / 21 / 2025, page 18 / 63 13 / 47 Table 1 Native Protein Category Functions Reference Transforming Growth Factor beta-3 (TGF beta 3) SKIN CONDITIONING Cytokine involved in cell differentiation, cell adhesion, and extracellular matrix formation. Controls wound healing by regulating skin and dermal cells. TGF-p3 plays a role in orofacial development and has a potent anti-scarring effect. Le M, Naridze R, Morrison J, Biggs LC, Rhea L, Schutte BC, Kaartinen V, Dunnwald M. Transforming growth factor Beta 3 is required for excisional wound repair in vivo. PLoS One. 2012;7(10):e48040. doi: 10.1371 / journal.pone.0048040. Epub 2012 Oct 26. PMID: 23110169; PMCID: PMC3482237. Hepatocyte Growth Factor (HGF) ANTIOXIDANT, SKIN CONDITIONER, HAIR CONDITIONER. Hepatocyte growth factor (HGF) is produced by stromal and mesenchymal cells and stimulates the proliferation, motility, morphogenesis, and angiogenesis of epithelial cells in various organs.Kato, T. (2017). Biological roles of hepatocyte growth factor-Met signaling from genetically modified animals (Review). Biomedical Reports, 7, 495-503. https: / / doi.org / 10.3892 / br.2017.1001. Petição 870250106689, de 21 / 11 / 2025, pág. 19 / 63 14 / 47 Keratinocyte Growth Factor (KGF or FGF-7) SKIN CONDITIONING KGF increases keratinocyte proliferation and migration, but delays differentiation. KGF expression is strongly upregulated in the injured dermis, and KGF accelerates wound closure, suggesting its importance in the healing process. KGF has been shown to protect epithelial cells from the toxic effects of reactive oxygen species. Susanna Karvinen, et al. Keratinocyte Growth Factor Migration and Hyaluronan Synthesis in the Epidermis by Activation of Keratinocyte Hyaluronan Synthases 2 and 3. Journal of Biological Chemistry. Volume 278, Issue 49, 2003. Pages 49495-49504. ISSN 00219258. https: / / doi.org / 10.1074 / jbc.M310445200. Hans-Dietmar Beer, et al. Expression and Function of Cacatinocyte Growth Factor and Activity in Skin Morphogenesis and Cutaneous Wound Repair, Journal of Investigative Dermatology Symposium Proceedings. Volume 5, Issue 1, 2000. Pages 34-39.https: / / doi.org / 10.1046 / j.10870024.2000.00009.x. Fibroblast Growth Factor 10 (FGF10) SKIN CONDITIONING FGF10 promotes fibroblast migration, which is important in promoting wound healing. Song YH, Zhu YT, Ding J, Zhou FY, Xue JX, Jung JH, Li ZJ, and Gao WY: Distribution of fibroblast growth factors and their roles in skin fibroblast cell migration. Mol Med Rep 14: 3336-3342, 2016. Petition 870250106689, dated 11 / 21 / 2025, p. 20 / 63 15 / 47 Beta Factor Nerve Growth Factor (NGF beta) Sirtuin 1 (SIRT 1) HAIR CONDITIONING, SKIN PROTECTION Nerve Growth Factor (NGF) is a polypeptide that, in addition to its effect on nerve cells, is believed to play a role in inflammatory responses and tissue repair. It plays important roles in tissue remodeling during the wound healing process in the skin. Micera A, et al. Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair. Proc Natl Acad Sci US A. 2001 May 22;98(11):6162-7. doi: 10.1073 / pnas.101130898. MasHAiko Mori, et al. The functions of nerve growth factor and nerve growth factor receptor in wound healing. 2012 Volume 16 Issue 3+4 Pages 5165. https: / / doi.org / 10.3353 / omp.16.51 ANTIOXIDANT, HAIR CONDITIONER, SKIN CONDITIONER Sirtuins are involved in the aging and photoaging process.The level of SIRT1 shows a variable expression profile according to age (decreasing with age). Sirtuin 1 plays a fundamental role in the epigenetic modification of proteins, histones, and chromatin, regulating Bielach-Bazyluk A, Zbroch E, Mysliwiec H, Rydzewska-Rosolowska A, Kakareko K, Flisiak I, Hryszko T. Sirtuin 1 and Skin: Implications in Intrinsic and Extrinsic Systematic Review-A. Cells. April 6, 2021;10(4):813. doi: 10.3390 / cells10040813. PMID: 33917352; PMCID: PMC8067363. GarciaPeterson L, M, Wilking-Busch M, J, Ndiaye M, A, Philippe C, G, A, Setaluri V, HAmad N: Sirtuins in Skin and Skin Cancer. Skin Pharmacol Physiol 2017;30:216-224. doi: 10.1159 / 000477417. Petition 870250106689, dated 11 / 21 / 2025, p. 21 / 63 16 / 47 Expression of genes related to oxidative stress response, inflammation, and apoptosis. It is used as an active ingredient in anti-aging cosmetic products. Sirtuin 2 (SIRT2) ANTIOXIDANT, HAIR CONDITIONER, SKIN CONDITIONER Like SIRT1, SIRT2 is implicated in aging, as well as damage caused by UV rays and oxidative stress responses. (same as Sirtuin 1) Tissue Inhibitor for Metalloproteinase 1 (TIMP 1) Tissue inhibitors for metalloproteinase 1 (TIMP 1) Tissue inhibitors for metalloproteinases (TIMPs) are the main endogenous inhibitors of matrix metalloproteinases (MMPs). TIMP-1 plays a key role in maintaining the balance between degradation and remodeling of the extracellular matrix. Elianne A. Koop, et al. CHAPTER 7 - TUMOR VASCULATURE AS A TARGET, Anticancer Drug Development, Academic Press, 2002, Pages 123cp2. KJ Leco, et al.MATRIX METALLOPROTEINASE INHIBITORS, Encyclopedia of Respiratory Medicine, Academic Press, 2006, Pages 9-18. https: / / doi.org / 10.1016 / B0-12-370879-6 / 00243-X. https: / / doi.org / 10.1016 / B978-0120726516 / 50008-5. Petition 870250106689, dated 11 / 21 / 2025, p. 22 / 63 17 / 47 Macrophage Colony-Stimulating Factor 1 (M-CSF or CSF 1) SKIN PROTECTION Macrophage colony-stimulating factor (M-CSF) is a hematopoietic growth factor that regulates the proliferation, differentiation, and functional activation of monocytes. It promotes the differentiation of myeloid progenitors into heterogeneous populations of monocytes, macrophages, dendritic cells, and osteoclasts, cells responsible for bone resorption. As a treatment, M-CSF shows therapeutic potential in tissue repair. David A. Hume, Therapeutic applications of macrophage colony-stimulating factor-1 (CSF1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood (2012) 119 (8): 1810-1820 https: / / doi.org / 10.1182 / blood-2011-09-379214 Platelet-Derived Growth Factor (PDGF) MOISTURIZER, SKIN CONDITIONER Platelet-Derived Growth Factor (PDGF) is a potent activator of cells of mesenchymal origin.PDGF stimulates chemotaxis, proliferation and Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. J Cell Biochem. 1991 Apr;45(4):319-26. doi: 10.1002 / jcb.240450403. PMID: 2045423. Petition 870250106689, dated 11 / 21 / 2025, p. 23 / 63 18 / 47 Expression of new genes in monocytes, macrophages, and fibroblasts in vitro, cell types considered essential for tissue repair. Stem Cell Factor (SCF) ANTIOXIDANT, HAIR CONDITIONER, SKIN CONDITIONER Stem Cell Factor (SCF) is a growth factor that binds to the tyrosine kinase receptor and leads to the activation of multiple signal transduction factors. SCF plays a role in the differentiation, survival, and self-renewal of hematopoietic stem cells. Atef A, El-Rashidy MA, Abdel Azeem A, Kabel AM. The Role of Stem Cell Factor in Hyperpigmented Skin Lesions. Asian Pac J Cancer Prev. 2019 Dec 1;20(12):3723-3728. doi: 10.31557 / APJCP.2019.20.12.3723 Vascular Endothelial Growth Factor A (VEGF-A) SKIN CONDITIONING Vascular Endothelial Growth Factor A regulates angiogenesis and vasculogenesis. Holmes, DI, Zachary, I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease.Genome Biol 6, 209 (2005). https: / / doi.org / 10.1186 / gb-2005-6-2-209. Petition 870250106689, dated 11 / 21 / 2025, page 24 / 63 19 / 47 Insulin-like Growth Factor (IGF-1) SKIN CONDITIONING, SKIN PROTECTION Insulin-like growth factor 1 (IGF-1) stimulates the proliferation of these fibroblasts, resulting in the formation of loose connective tissue. It acts on epidermal keratinocytes, stimulating their proliferation. Farag AGA, Abdu AllHA AMK, El-Rebey HS, Mohamed IbrHAeem KI, Mohamed ASED, Labeeb AZ, Elgazzar AE, Haggag MM. Role of insulin-like growth factor-1 in skin tags: a clinical, genetic and immunohistochemical study in a sample of Egyptian patients. Clin Cosmet Investig Dermatol. 2019 Apr 26;12:255-266. doi: 10.2147 / CCID.S192964. PMID: 31118729; PMCID: PMC6503204. Fibroblast Growth Factor 1 (FGF 1 or aFGF) — FGFs have biological activity that stimulates fibroblast proliferation and angiogenesis. They play an important role in the repair and remodeling of the dermis during the anti-aging process of the skin and can act in cell regeneration and repair processes.de Araújo R, Lôbo M, Trindade K, Silva D, F, Pereira N: Fibroblast Growth Factors: A Controlling Mechanism of Skin Aging. Skin Pharmacol Physiol 2019;4:275-282. doi: 10.1159 / 000501145. Petition 870250106689, dated 11 / 21 / 2025, p. 25 / 63 20 / 47 Interleukin 10 (IL-10) MOISTURIZER, SKIN CONDITIONER Interleukin 10 (IL-10) is a cytokine with potent anti-inflammatory properties that plays a central role in limiting the host's immune response to pathogens, preventing host damage and maintaining normal tissue homeostasis. In the skin, it facilitates regenerative healing by regulating the extracellular matrix and the cellular function of fibroblasts and endothelial progenitor cells. King A, Balaji S, Le LD, Crombleholme TM, Keswani SG. Regenerative Wound Healing: The Role of Interleukin-10. Adv Wound Care (New Rochelle). 2014 Apr 1;3(4):315-323. doi: 10.1089 / wound.2013.0461. PMID: 24757588; PMCID: PMC3985521. Transforming Growth Factor Beta 1 (TGFβ1) SKIN CONDITIONING Transforming Growth Factor β (TGFβ) plays a fundamental role in cell proliferation, differentiation, and apoptosis. It is involved in wound healing, angiogenesis, and immunoregulation. Prud'homme, G.Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87, 1077-1091 (2007). https: / / doi.org / 10.1038 / labinvest.3700669. Petição 870250106689, de 21 / 11 / 2025, pág. 26 / 63 21 / 47 Basic Fibroblast Growth Factor (FGF 2 or bFGF) SKIN CONDITIONING FGFs have biological activity that stimulates fibroblast proliferation and angiogenesis. They play an important role in the repair and remodeling of the dermis during the anti-aging process of the skin and can act in cell regeneration and repair processes. bFGF is widely accepted and used in clinical practice to accelerate wound healing. de Araújo R, Lôbo M, Trindade K, Silva D, F, Pereira N: Fibroblast Growth Factors: A Controlling Mechanism of Skin Aging. Skin Pharmacol Physiol 2019;4:275-282. doi: 10.1159 / 000501145. Akita S, Akino K, Hirano A. Basic Fibroblast Growth Factor in Scarless Wound Healing. Adv Wound Care (New Rochelle). 2013 Mar;2(2):44-49. doi: 10.1089 / wound.2011.0324. PMID: 24527324; PMCID: PMC3623580.Insulin-like Growth Factor 2 (IGF-2) SKIN CONDITIONING Insulin-like Growth Factor 2 (IGF-2) regulates cell proliferation, growth, migration, differentiation, and survival. Bergman D, Halje M, Nordin M, Engstrom W: Insulin-Like Growth Factor 2 in Development and Disease: A Mini-Review. Gerontology 2013;59:240-249. doi: 10.1159 / 000343995. Petition 870250106689, dated 11 / 21 / 2025, page 27 / 63 22 / 47

[0054] Based on the studies carried out so far, we can say with certainty that FGF2 and type 1 collagen are present in CCM, as can be seen in Tables 2A and 2B: Table 2A: Batch CCM Collagen type 1 pg / ml Batch 1 357.6 Batch 2 456.7 Batch 3 404.3 Batch 4 387.5 Table 2B: CCM FGF2 batches pg / ml Batch 1 64.7 Batch 2 54.6 Batch 3 36.4

[0055] Concentrated Conditioned Medium (CCM) is a conditioned medium obtained from fibroblast culture without any component of animal origin. At the end of the process of the present invention, steps c. and d., the collected concentrated conditioned medium was optionally sterile filtered. The final product contained a mixture of growth factors and cytokines secreted by fibroblasts, along with matrix proteins that are useful for tissue regeneration.

[0056] CCM contains approximately 10-50 pg / ml of proteins with different molecular weights. Petition 870250106689, dated 11 / 21 / 2025, page 28 / 63 23 / 47

[0057] Table 3 shows the quantification of the protein content of CCM with micro BCA. Table 3: Batch CCM OD1 OD2 Average blank Protein concentration (pg / ml) Batch 1 0.1806 0.1800 0.066400006 11 Batch 2 0.2673 0.2772 0.1578500005 73 Batch 3 0.1649 0.1671 0.052100003 15 Batch 4 0.2670 0.2802 0.159699999 74

[0058] This heterogeneous group of proteins is referred to in the literature as the fibroblast secretome. Inside it, numerous proteins are found, some of which are still unidentified. Figure 1 shows the result of an electrophoresis of the protein content of the fibroblast.

[0059] The main molecules present in the fibroblast secretome and, consequently, in the MCC, are: Vascular Endothelial Growth Factor (VEGF), Transforming Growth Factor β (TGF-β) and Fibroblast Growth Factors (FGFs). These latter factors play a relevant role in collagen deposition in the extracellular matrix and in anti-aging therapy, since the synthesis of collagen and elastin is responsible for the elasticity and resistance of the skin, characteristics that decrease with skin aging.

[0060] Other growth factors, such as Platelet-Derived Growth Factor (PDGF), Granulocyte Colony-Stimulating Factor (G-CSF), Keratinocyte Growth Factor (KGF), and Hepatocyte Growth Factor (HGF), are implicated in dermal remodeling. Petition 870250106689, dated 11 / 21 / 2025, page 29 / 63 24 / 47 stimulating the synthesis of new collagen, elastin, and glycosaminoglycans, in addition to mediating angiogenesis. Without adhering to any specific theory, in order to clarify the mechanism of action of CCM, a co-culture test was performed to verify whether the secretome components were released from fibroblasts into the culture medium and whether these influenced a second population of fibroblasts. The aim of the assay was to simulate a physiological condition in which different populations of fibroblasts reside in the same skin tissue.

[0061] The behavior of fibroblasts was studied using a transwell system. It was possible to study the indirect interaction of two different cell populations incubated together that have in common only the culture medium (Example 6).

[0062] In another embodiment, the cosmetic product of the present invention can be obtained by a process in which the sonicated hyaluronic acid comprises sonicated hyaluronic acid fragments with a size of 1200 kDa to 80 kDa in varying amounts, for example, in amounts of about 9% of fragments from 1200 to 800 kDa, about 32-33% of fragments from 800 to 400 kDa, about 34-35% of fragments from 400 to 200 kDa and about 15% of fragments from 200 to 80 kDa.

[0063] One of the most important characteristics of HA is represented by its molecular weight. Molecular weight determines the properties of HA and is essential for determining the permeability of the molecule to the skin. Petition 870250106689, dated 11 / 21 / 2025, page 30 / 63 25 / 47

[0064] Morphologically, if the polymer is short, it unfolds more easily and has an advantage in terms of movement (medium / low molecular weight HA). The longer the polymer, the more voluminous and slower it is (high molecular weight HA).

[0065] High molecular weight HA (above 500 kDa) cannot be absorbed by the skin and exerts its action on the epidermis. In fact, when applied to the skin's surface, high molecular weight HA acts by forming a hydrated viscoelastic film. This film is permeable to air, therefore cutaneous respiration is not obstructed while the film fixes moisture on the skin's surface. Moreover, the most important advantage of high molecular weight hyaluronic acid is its good water retention capacity; thus, once applied to the skin, HA functions primarily as a film-forming polymer: it reduces water evaporation, with an action similar to that of an occlusive. Furthermore, the film-forming action of HA allows, through mechanical means, the reduction of evaporation from the skin and limits interaction with environmental factors such as temperature, humidity, and UV radiation. In this way, the protective barrier of HA improves skin hydration and promotes local healing of superficial wounds.

[0066] Medium / low molecular weight HA is able to perform its function in the deeper layers of the skin, reaching the dermis. Because they are smaller, they encounter fewer obstacles when crossing the epidermis and perform their functions in the dermis.

[0067] HA is a fundamental component of the extracellular matrix of the dermis, as it stimulates proliferation and migration. Petition 870250106689, dated 11 / 21 / 2025, page 31 / 63 26 / 47 of fibroblasts, endothelial cells and keratinocytes, in addition to promoting neoangiogenesis. Thanks to its action in the deeper layers of the skin, HA manages to maintain a high level of hydration in the deep epidermis, improving skin tone and elasticity.

[0068] The contribution of medium / low molecular weight HA is essential to assist in the physiological maintenance of the extracellular matrix in the dermis.

[0069] In order for HA to act on both skin layers (outer and inner layers), part of the HA in the cosmetic product of the present invention is fragmented by sonication. The instrument used for HA sonication was the Sonicated Sonics Vibracell model VCX 130 SN 40225L, at a frequency of 100%, for 10 minutes, with 10-second on / 10-second off intervals. Other instruments can be used to obtain the resulting fragments in different size ranges; what needs to be taken into consideration are the instrument settings, which must be adapted to the scope.

[0070] The fragmentation process occurs through physical and not chemical agents, in order to avoid reaction intermediates or processing residues that could be harmful (Example 7).

[0071] In another embodiment, the cosmetic product of the present invention can be obtained by a process in which said cosmetic product is in the form of a cream or serum and further comprises cosmetically acceptable excipients. Petition 870250106689, dated 11 / 21 / 2025, pp. 32 / 63 27 / 47

[0072] The cosmetic product may be formulated as a facial cosmeceutical cream, lotion and / or serum for topical application, with or without growth factors, peptides and / or other proteins and additional biologically active substances. In addition to the active ingredients, the product may comprise cosmetically acceptable excipients, such as emollients, water-retaining agents, moisturizers, vitamins, antioxidants, anti-irritants and soothing agents.

[0073] The cosmetic product of the present invention has surprisingly demonstrated positive effects in promoting the natural regeneration of the dermis in different cases, such as: post-laser and post-radiotherapy treatments, scars, wrinkles, various types of irritation (redness and sun irritation).

[0074] In a second aspect, the invention therefore provides for the use of the cosmetic product to promote tissue regeneration. In a third aspect, the cosmetic product according to the invention can be used to improve skin texture.

[0075] In a fourth aspect, the invention relates to the use of the cosmetic product to reduce wrinkles on the skin.

[0076] In a fifth aspect, the invention relates to the use of the cosmetic product to reduce scars.

[0077] In a sixth aspect, described here is the use of the cosmetic product to reduce skin irritation and blemishes.

[0078] Several embodiments and aspects of the present invention, as outlined above and claimed in the claims section below, find experimental support in the following examples. EXAMPLES Petition 870250106689, dated 11 / 21 / 2025, pp. 33 / 63 28 / 47

[0079] Reference is now made to the following examples which, together with the descriptions above, illustrate some embodiments of the invention.

[0080] Tissue samples were obtained with the prior informed consent of the donors.

[0081] The production of Concentrated Conditioned Medium (CCM) involved the selection of a suitable donor of skin or umbilical cord (discarded tissue), in accordance with the European Directive on the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells (2004 / 23 / EC, 2006 / 17 / EC and subsequent national updates and transpositions).

[0082] All human tissue samples were preserved in a specific transport medium and sent via a qualified delivery service, with controlled transport at 2-8 °C, to an authorized cell factory.

[0083] Upon arrival, after verifying the integrity of the packaging, the serological report and the temperature record, the tissue was subjected to digestion using specific GMP grade enzymes (neutral protease, collagenase and hyaluronidase).

[0084] The enzymes used for tissue digestion were generally lyophilized and then reconstituted according to the manufacturer's instructions. Example 1: ISOLATION OF SKIN CELLS Digestion with neutral protease

[0085] To digest pieces of tissue the size of 1 cm2: Petition 870250106689, dated 11 / 21 / 2025, pp. 34 / 63 29 / 47

[0086] 7 mL of digestion solution were prepared by adding a volume of neutral protease equivalent to 6 DMCU (1.2 mL) and completing the volume with Hanks' balanced saline solution (HBSS). 14 pL of 1M CaCl2 solution were added to obtain a 2mM solution. 1 unit of DMC catalyzes the cleavage of 1 pmol of dimethylcasein peptide bond per minute at 25 °C, pH 7.0, expressed in terms of newly formed terminal amino groups, determined with TNBS1.

[0087] Before proceeding with digestion with neutral protease, 2 washes were performed with a DPBS solution with antibiotic (penicillin-streptomycin) and 2 washes with Dulbecco's phosphate-buffered saline (DPBS) only.

[0088] After washing, the skin sample was placed in a tube containing the digestion solution and incubated at 2-8 °C overnight.

[0089] For larger tissue samples, sections were cut into smaller pieces with a scalpel and the proportional volume was used for the digestion method described above. Dermis / epidermis separation, digestion with collagenase, and seeding in a flask.

[0090] After removal of the neutral protease, the sample was washed with DPBS, transferred to a Petri dish to perform dermis / epidermis separation. After removal of the epidermis, the dermis was fragmented into small pieces. The fragments were placed in a tube prepared with 10 mL of collagenase solution (0.3 PZU / mL in HBSS) and 20 µL of a 1M CaCl2 solution (final solution of 2 mM). The sample was Petition 870250106689, dated 11 / 21 / 2025, page 35 / 63 30 / 47 incubated for 2 h at 37 °C in an incubator. PZU: 1U, according to Wünsch, catalyzes the hydrolysis of 1 μmol of 4phenylazobenzyloxycarbonyl-L-prolyl-L-leucylglycyl-L-prolyl-Darginine per minute at 25 °C and pH 7.1.

[0091] At the end of the 2-hour digestion, the digestion solution was filtered with a 100 μm filter. The filter was washed with 10 mL of HBSS and centrifuged at 1500 rpm for 10 minutes.

[0092] The supernatant was discarded, the sediment resuspended in 10 mL of complete medium (CM), and the total cell suspension was seeded into T25 flasks and incubated in an oven at 37 °C and 5% CO2 for 2 to 4 days. Materials: a. Preparation of Neutral Protease:

[0093] The lyophilized enzyme was initially resuspended to obtain 100 DMCU / mL and then diluted to 5 DMCU / mL. The solution was sterilely filtered and divided into 1.5 mL aliquots. The vials were labeled with the product name, batch number, concentration, and expiration date (1 year after reconstitution). b. Collagenase Preparation:

[0094] The lyophilized enzyme was initially resuspended in 1 mL to obtain the stock solution (PZU / mL according to the concentration indicated in the certificate of analysis).

[0095] To prepare a working solution, the stock solution was diluted and sterilely filtered to obtain aliquots with a concentration of 3PZU. The solution must be kept constantly on ice until use. The vials were Petition 870250106689, dated 11 / 21 / 2025, pp. 36 / 63 31 / 47 identified with the product name, batch, concentration and expiration date (1 year after reconstitution). c. Preparation of the complete medium (CM):

[0096] The culture medium composed of DMEM, glutamine, sodium pyruvate, and fetal bovine serum (irradiated and certified by EDQM) was identified as: Complete Medium (CM) and its formula was as follows: - 500 mL of DMEM (high glucose) - 50 mL of FBS - 10 mL of 200 mM glutamine - 5 mL of 1M sodium pyruvate.

[0097] All components of the medium were sterile, the preparation was carried out under a laminar flow hood (grade A) with a grade B environment, the components were sterilely added to the vial containing DMEM. Example 2: Cellular Isolation of the Umbilical Cord Digestion with hyaluronidase and collagenase and seeding in a flask.

[0098] The cord sample was washed with DPBS, transferred to a Petri dish for separation into small pieces, and then ground into a fine mass. The tissue mass was placed in a 50 mL tube and an equal volume of DPBS was added, along with an amount of hyaluronidase and collagenase equivalent to 1% of the final volume and an amount of calcium gluconate equivalent to 0.04% of a 10% calcium gluconate solution. The sample was incubated for 2 hours at 37 °C in an incubator. Petition 870250106689, dated 11 / 21 / 2025, pp. 37 / 63 32 / 47

[0099] At the end of digestion, the sample was diluted with DPBS (1:1), centrifuged at 300g for 10 seconds to settle all undigested debris, and the digestion solution was passed through a 1 mm filter and then through a 100 g filter. The solution was centrifuged at 450 rpm for 7 minutes.

[0100] The supernatant was discarded, the pellet was resuspended in 25 mL of complete medium (CM), and the total cell suspension was seeded into a T 150 flask and incubated in an incubator at 37°C and 5% CO2 for 2 to 4 days. Materials: a. Hyaluronidase Preparation:

[0101] The lyophilized enzyme was resuspended to obtain a 10 KU / mL solution. The solution was sterilely filtered and divided into 1 mL aliquots. The vials were labeled with the product name, batch number, concentration, and expiration date (1 year after reconstitution). b. Collagenase Preparation:

[0102] The lyophilized enzyme was resuspended to obtain a 50 mg / ml solution. The solution was sterilely filtered and divided into 1 ml aliquots.

[0103] The bottles were identified with the product name, batch, concentration and expiration date (1 year after reconstitution). c. Preparation of the complete medium (CM):

[0104] The culture medium consisted of DMEM with low glucose concentration, fetal bovine serum (irradiated and certified by EDQM), human platelet lysate (HPL), and heparin. The Complete Medium (CM) formula was as follows: - 500 mL of DMEM (low glucose) Petition 870250106689, dated 11 / 21 / 2025, pp. 38 / 63 33 / 47 - 15 mL of FBS - 15 mL of HPL - 2.5 mL of heparin (1000 U / mL)

[0105] All components of the medium were sterile, the preparation was carried out under a laminar flow hood (grade A) with a grade B environment, the components were sterilely added to the vial containing DMEM. Example 3: CELL EXPANSION AND INOCULATION IN A BIOFACTORY EXPANSION:

[0106] After the isolation of fibroblasts, the expansion scale was identical for the two different tissues in Examples 1 and 2, with only the cell expansion medium changing. The medium for dermal fibroblasts is described in Example 1, while the medium for umbilical cord fibroblasts is described in Example 2.

[0107] The nutrient deprivation method is the same for both tissue samples.

[0108] When the cells reach a confluence of about 80%, observable under a microscope, the fibroblasts are detached from the flask using trypsin, counted, and seeded into new T150 flasks. A series of expansions, from 1 T150 to The T150 and 3 to 12 T150 ratios allow obtaining the necessary quantity of cells to inoculate 2 to 3 biofactories with 1 L of complete medium. All steps were performed maintaining the same culture conditions (37 °C and 5% CO2), changing the medium every 2 to 4 days until confluence was reached. STARVATION:

[0109] Upon reaching confluence in the biofactories, the complete medium (DMEM, glutamine, sodium pyruvate, FBS) was removed Petition 870250106689, dated 11 / 21 / 2025, pp. 39 / 63 34 / 47 and, after two washes with DPBS, 1 L of incomplete medium (DMEM without phenol red, glutamine, sodium pyruvate) was added to each biofactory for 48 h. Nutrient deprivation for 48 h had the effect of stimulating the release of regenerative factors in the culture medium. After this incubation period, the medium was collected in sterile flasks and centrifuged to remove cellular debris. The supernatant was filtered with 0.22 µm (500 ml) filter systems, the flasks were identified with the code, and the batch was frozen at -20 °C. Example 4: CONCENTRATION OF THE CONDITIONED MEDIUM BY TANGENTIAL FLOW FILTRATION (FFT)

[0110] This type of concentration allows the process to be accelerated and larger quantities of supernatant to be used, on the order of liters.

[0111] The FFT concentration process was carried out by defining the following operational parameters: Phase I: concentration 10 X Phase II: Diafiltration with 10 volumes of buffer (0.9 NaCl) %) Phase III: concentration 20 X (final) Transmembrane pressure (TMP): 0.3 bar Flow: 500 ml / min Cut-off of 10 kDa

[0112] The defined parameters allowed obtaining an average permeate flow of approximately 54 ml / min or approximately 20 L / m2 / h and a shear stress of approximately 2300 / 2400 s-1. Phase I concentration, Phase II diafiltration and Phase Petition 870250106689, dated 11 / 21 / 2025, pp. 40 / 63 35 / 47 The concentration tests lasted 32 minutes, 30 minutes, and 2 minutes, respectively.

[0113] The system was then emptied to recover all the product in the chosen bag / container and filtered through 0.22 mm syringe filters, and subsequently divided into aliquots. All aliquots were frozen at -20 °C. Example 5: CONCENTRATED CONDITIONED MEDIUM RELEASE TEST: PROTEIN DETERMINATION

[0114] The quantification of the protein content of CCM was performed using the bicinchoninic acid (BCA) protein assay. The bicinchoninic acid (BCA) protein assay, also known as the Smith assay, is a highly sensitive colorimetric assay compatible with solubilized protein solutions.

[0115] The amount of protein present in a solution can be quantified by measuring the absorption spectrum and comparing it with protein solutions of known concentrations.

[0116] A standard albumin curve was used in the test. After 2 hours of incubation, the samples were read at 562 nm. The average absorbance at 562 nm of the blank standards was subtracted from the average absorbance at 562 nm of each standard and each sample.

[0117] A standard curve was plotted by placing the concentration of the standards on the X-axis and the absorbance on the Y-axis.

[0118] The standard curve obtained was used to determine the protein concentration of each unknown sample. Example 6: CHARACTERIZATION OF THE CONDITIONED ENVIRONMENT

[0119] The behavior of fibroblasts, to study the indirect interaction of two different cell populations, Petition 870250106689, dated 11 / 21 / 2025, pp. 41 / 63 36 / 47 was studied using a transwell system, which is a co-culture method. With this system, the cells were incubated together and only shared the culture medium.

[0120] The transwell system provided an outer chamber where, at the bottom of which, a population of fibroblasts was cultured, and an inner chamber with a porous membrane on which a second population of fibroblasts was placed.

[0121] The two populations were not in direct contact and the transwell system allowed the passage of molecules released by the cells in the upper compartment towards the cells in the lower compartment.

[0122] The tests were performed with two populations of normal fibroblasts (referred to as population 1 and population 2) that were not frozen and with one normal population and one population of frozen BLAST fibroblasts (frozen in modified Tyrode solution).

[0123] After 48 hours and 8 days, the expression level of two markers related to tissue regeneration was analyzed: HMGB1 and type 1 collagen.

[0124] Only the results for normal fibroblast populations 1 and 2 are listed in the document.

[0125] When population 1 is co-cultured with population 2, an increase in the production of the signaling molecule HMGB1 is observed after 48 hours and of type 1 collagen after 8 days in the fibroblast population 1. This demonstrates that fibroblasts release factors into the culture medium that can stimulate the surrounding environment through a paracrine effect (Figure 3). Petition 870250106689, dated 11 / 21 / 2025, pp. 42 / 63 37 / 47

[0126] Similar results were found in the co-culture assay of normal fibroblast and frozen BLAST fibroblast. Example 7: Hyaluronic Acid Sonication Method

[0127] The fragmentation process occurs through physical and not chemical agents, in order to avoid reaction intermediates or processing residues that may be harmful.

[0128] 0.25% high molecular weight hyaluronic acid (HMW-HA of approximately 2,200-1,800 kDa) in physiological solution was sonicated at 100% frequency for 10 minutes, with 10-second ON and 10-second OFF intervals (Sonicated Sonics Vibracell model VCX 130 SN 40225L). The time, setting, and frequency chosen for the HA sonication method are also important to avoid the formation of small fragments with a pro-inflammatory nature, which would be created with enzymatic fragmentation.

[0129] The products of the invention may contain a mixture of HA with different molecular weights, sonicated or non-sonicated.

[0130] In the creams, there is 0.25% sonicated high molecular weight (HMW) HA, while in the serum there is 0.15% sonicated high molecular weight (HMW) HA and 0.1% low molecular weight (LMW) HA.

[0131] To verify HA fragmentation, it was applied to a 1% agarose gel with reference samples and subjected to an electrophoretic run (Figure 4). Petition 870250106689, dated 11 / 21 / 2025, pp. 43 / 63 38 / 47

[0132] Each sample is distributed in a diffuse pattern. The diffuse pattern is composed of HA fragments of different lengths: the upper part coincides with larger fragments which, being more voluminous, flow less within the gel, while the lower part of the diffuse pattern comprises smaller fragments. For example, the diffuse pattern of 1000 kDa HA (sample 6) remains in the upper part of the gel.

[0133] The HA in Blast creams (sample 1) shows a diffuse pattern similar to that of the standard 250 kDa HA marker (sample 5).

[0134] To obtain more precise information on the distribution status of HA fragments, the HA smear on Blast creams (sample 1) and Blast serum (sample 4) was divided into squares of the same size and the color intensity of each interval was quantified (in pixels using the ImageJ program) in relation to the standards. The more intense the color, the greater the amount of fragment. The values ​​were entered into a graph and the percentages were obtained (Figure 5).

[0135] The molecular weight of HA in creams and serum is distributed according to a Gaussian curve characterized by HA of medium-high and medium-low molecular weight.

[0136] The composition of HA in the creams and HA in the serum is described in Table 4. Table 4: Dimensions of HA HA in creams (a product of the invention) HA in serum (a product of the invention) 1200-800 kDa 9% 11% 800-400 kDa 32.5% 41% 400-200 kDa 34.5% 37% 200-80 kDa 15% 11% Petition 870250106689, dated 11 / 21 / 2025, pp. 44 / 63 39 / 47

[0137] The distribution ensures the advantage of both medium-high and medium-low molecular weights. The specific size of the polysaccharide allows it to exert its action both in the epidermis (fragments larger than 500 kDa), giving the skin characteristics of elasticity, hydration and softness, and in the dermis (fragments smaller than 500 kDa), assisting in the physiological maintenance of the extracellular matrix and in its anti-inflammatory action. Example 8: HA + CONDITIONED ENVIRONMENT: STABILITY AND PROTECTION

[0138] The cosmetic product of the present invention results from the combination of hyaluronic acid (HA) and Concentrated Conditioning Medium (CCM).

[0139] To provide evidence on how the quality and stability of an ingredient vary over time under the influence of environmental factors (temperature, humidity, light) and other components / ingredients, a stability test was performed.

[0140] In this experiment, the stability of HA was evaluated in the presence of CCM, the concentrated conditioned medium obtained from human fibroblasts cultured in vitro. The integrity status of HA was evaluated by gel electrophoresis after 14 days.

[0141] The results clearly demonstrate that there are no significant differences in size between isolated HA and HA mixed with CCM: the polysaccharide has the same size, no small fragments are formed, and there are no visible aggregates. It is concluded that CCM does not affect the integrity of HA. Petition 870250106689, dated 11 / 21 / 2025, pp. 45 / 63 40 / 47

[0142] The stability of sonicated HA fragments is important for them to exert their action in both the epidermis and the dermis. To penetrate the epithelial layer, HA is subject to a series of interactions with the surrounding environment. Hyaluronidase, a potent inhibitor of HA action that catalyzes the degradation of the polypeptide, is present in the skin. While its action can be advantageous for high molecular weight HA (over 1000 kDa), as it breaks it down into smaller pieces that are more easily absorbed by the skin, random degradation leads to the formation of small HA fragments that can result in a pro-inflammatory effect.

[0143] To understand how CCM can assist in the presence of this enzyme, which is physiologically present in the skin, an enzymatic assay was prepared. This test aims to simulate the physiological situation of the epidermis.

[0144] The aim of this study was to obtain quantitative data, not just qualitative data, in order to demonstrate that the presence of CCM has the ability to stabilize HA against attack by hyaluronidases.

[0145] This test explores the ability of long-chain hyaluronic acid to create turbidity in a solution containing albumin. Turbidity is a function of HA concentration. The greater the turbidity, the greater the presence of HA. If HA is cleaved by hyaluronidase, it will no longer be able to form a network with albumin and the solution will become clear. The decrease in turbidity is linked to the fragmentation of HA by the enzyme. Petition 870250106689, dated 11 / 21 / 2025, pp. 46 / 63 41 / 47 Table 5: Enzyme competition assay with hyaluronidase Test with 5pg OD (1) OD (2) OD (3) Average OD Average OD — blank Undigested HA mg HA — mg HA in CCM % CCM protection of HA % enzymatic degradation of HA HA 0.0652 0.0653 0.0634 0.0646 0.0203 4.348 HA + Hiase 0.0453 0.0456 0.0445 0.0451 0.0008 0.109 2.5 97.5 HA + CCM Batch 1 + Hiase 0.0732 0.0743 0.0728 0.0734 0.0291 6.261 4.21 96.83 3.17 HA + CCM Batch 1 0.0753 0.0752 0.0746 0.075 0.0307 6.609 4.558 CCM Batch 1 + Hiase 0.0517 0.0524 0.0581 0.0541 0.0097 2.051 0 Blank (buffer enzyme only) 0.0447 0.0451 0.0432 0.0443 0

[0146] The data obtained and presented in Table 5 indicate that HA alone, in the presence of the enzyme, was almost completely degraded (97.5%), while HA in combination with CCM was minimally degraded (3.17%).

[0147] The competitive assay demonstrated the protective capacity of CCM in relation to HA when attacked by the enzyme.

[0148] The protective action of CCM in favor of HA stability may be due to the sum of several factors. In fact, there appear to be hyaluronidase inhibitors and / or antioxidants in CCM that lead to less HA fragmentation. In addition, it is plausible that small enzymatic proteins exist in CCM. Petition 870250106689, dated 11 / 21 / 2025, pp. 47 / 63 42 / 47 capable of chemically modifying the polysaccharide structure, making it more stable.

[0149] From the two tests performed, it is concluded that sonicated HA has an adequate size for both epidermal and dermal action, and that it is capable of interacting with CCM proteins (through hydrophobic (charge-charge) interactions and / or hydrogen bonds), forming a new compound with new characteristics, i.e., more stable and less sensitive to the action of hyaluronidase. The interaction between HA and proteins was also explored for protein transport at the subepithelial level. The result is an intradermal action of the mixture.

[0150] Furthermore, these data highlight the robustness and effectiveness of the cosmetic product of the invention. Example 9: HA + CONDITIONED MEDIUM: STABILITY AND PROTECTION: in vitro EFFICACY

[0151] A wound healing assay is an in vitro technique for investigating collective cell migration. It is also called a scratch assay, as it is performed by scratching a monolayer of cells and capturing images at the beginning and at regular intervals during cell migration to close the wound, comparing the images to quantify the rate of cell migration.

[0152] The scratch test is a great tool for studying cell migration, since this mechanism is involved in many different physiological aspects. Cell migration plays a fundamental role in skin re-epithelialization and therefore the study of migration Petition 870250106689, dated 11 / 21 / 2025, pp. 48 / 63 43 / 47 Cellular may provide advances in understanding difficult-to-heal wounds.

[0153] This assay was used to verify the ability of fragmented HA with an additional component, the conditioned medium (CCM), to promote the natural cell migration of fibroblasts or keratinocytes, mimicking wound healing.

[0154] On the first day, a scratch is made in the cell monolayer. The cells are incubated with essential medium to simulate a physiological condition or with a combination of HA and CCM. The scratch appears as a cell-free space and is photographed in the same position at time 0 and after 24 hours. During this period, cells migrate to the empty space, attempting to close the gap. Image analysis is performed using the TScratch program and the percentage of cell migration area is calculated (Figures 6 and 7).

[0155] Fibroblasts (Figures 6A-D) and keratinocytes (Figures 7A-D) incubated with the cosmetic product of the invention closed the lesion space more rapidly when compared with cells treated with essential medium. The cosmetic product facilitated natural cell migration after injury.

[0156] From the scratch test, it was deduced that the two components together have a strengthening and synergistic effect in relation to their isolated action: the mechanical viscoelastic properties of HA assist in the physiological regeneration of the dermis and the combination with CCM demonstrates a stabilizing action on HA. Example 10: INCI PRODUCTS Petition 870250106689, dated 11 / 21 / 2025, pp. 49 / 63 44 / 47

[0157] The following tables show the components of some of the cosmetic products of the invention.

[0158] Rich Cream (Table 6), Light Cream (Table 7), Serum (face and / or body) (Table 8) and Hair Serum (Table 9). Table 6: Product Ingredients Function % RICH CREAM SODIUM HYALURONATE Functional ingredient 0.250 Concentrated Conditioning Medium Functional ingredient / HA stabilizer 0.250 3-O-ETHYL ASCORBIC ACID Antioxidant 0.170 AQUA Solvent 73.230 CAPRYLIC / CAPRIC TRIGLYCERIDE Skin conditioner / Perfume 6.000 CETEARYL ETHYLHEXANOATE Skin conditioner / Emollient 4.000 DIISOOSTEAROYL POLYGLYCERYL DILINOLEATE DILINOLEATE Skin conditioner / Emollient 3.000 ISONONANOATE Antistatic / Skin conditioner / Emollient 2.500 Cyclopentasiloxane Skin Conditioner / Emollient 2.375 OCTYLDODECANOL Skin Conditioner / Emollient / Scent 2.000 GLYCERIN (heptHAhydrate) Humectant / Viscosity Control 2.000 MAGNESIUM SULFATE Volume / Viscosity Control 1.000 PHENOXYETHANOL Preservative 0.800 BEESWAX Emulsifier / Emollient 0.500 Butyrospermum Parkii Butter Skin Conditioning / Viscosity Control 0.500 C12-15 Alkyl Ethylhexanoate Skin Conditioner / Emollient 0.500 Hydrogenated Castor Oil Skin Conditioner / Viscosity Controller / Emollient 0.500 Imidazolidinyl Urea Preservative 0.300 Cyclohexasiloxane1 Skin Conditioner 0.125 Petition 870250106689, dated 11 / 21 / 2025, pages 50 / 63 45 / 47 Table 7: Product Ingredients Function % Light Cream AQUA Solvent 86.180 HEPTYL UNDECILLATE Skin conditioner / emollient 5.000 METHYL GLUCOSE SESQUISTEARATE Surfactant, emulsifier 2.000 POLYGLYCERYL-3 METHYL GLUCOSE DISTEARATE Surfactant, emulsifier 1.500 SIMMONDSIA CHINENSIS SEED OIL Skin conditioner / emollient 1.000 Butyrospermum Parkii BUTTER Skin conditioning / Viscosity control 1.000 STEARYL CITRATE / OCTADODECYL CROSSPOLYMER Humectant 0.800 CAPRYLYL GLYCOL Skin conditioner / emollient 0.700 ACRYLATES / ACRYLATE CROSSPOLYMER ALKYL C10-30 Emulsion stabilizer, film former, viscosity controller 0.300 Concentrated conditioning medium Functional ingredient / HA stabilizer 0.250 SODIUM HYALURONATE Functional ingredient 0.250 ARGININE Buffering, skin conditioning 0.200 IMIDAZOLIDINYL UREA Preservative 0.200 GLYCERYL CAPRYLATE Skin conditioner / emollient 0.200 mg 3-O-ETHYL ASCORBIC ACID Antioxidant 0.170 mg XANTHAN GUM Gel former, emulsion stabilizer, viscosity controller 0.150 mg ETHYLHEXYLGLYCERIN Skin conditioner 0.100 mg Table 8: Product | Ingredient | Function | % | Serum | Sodium Hyaluronate | Functional ingredient | 0.250 | Concentrated Conditioning Medium | Functional ingredient / HA stabilizer | 0.250 | 3-O-Ethyl Ascorbic Acid | Antioxidant | 0.170 Petition 870250106689, dated 11 / 21 / 2025, pages 51 / 63 46 / 47 AQUA Solvent 96.140 PHENOXYETHANOL Preservative 0.830 LACTIC ACID Buffer / Humectant 0.600 SODIUM TAURATE POLYACRYLOYLDIMETHYL Emulsion stabilizer / Viscosity control 0.600 SODIUM LACTATE Buffer / Humectant / Keratolytic 0.400 IMIDAZOLIDINYL UREA Preservative 0.160 SODIUM HYDROXIDE Buffer / Denaturant 0.400 BUTYLENE GLYCOL Humectant / Skin conditioner / Viscosity control 0.000580 HYALURONIC ACID Functional ingredient 0.000072 SILANETRIOL Conditioner 0.000048 SORBIC ACID Preservative 0.000048 0 CITRIC ACID Buffer / Chelator 0.000048 0 Table 9: Product Ingredients Function % Hair Serum SODIUM HYALURONATE Functional ingredient 0.250 Concentrated Conditioner Functional ingredient / HA stabilizer 0.250 — 0.375 — 0.5 - 1 AQUA Solvent 98.399 PHENOXYETHANOL Preservative 0.800 SODIUM POLYACRYLOYLDIMETHYL TAURATE Emulsion stabilizer / viscosity controller 0.100 IMIDAZOLIDINYL UREA Preservative 0.200 BUTYLENE GLYCOL Humectant / skin conditioner / viscosity controller 0.0003500 HYALURONIC ACID Functional ingredient 0.0000450 SILANETRIOL Conditioner 0.0000300 SORBIC ACID Preservative 0.0000300 Citric Acid Buffering / Chelating Agent 0.0000300 Petition 870250106689, dated 11 / 21 / 2025, pages 52 / 63 47 / 47

[0159] From the description above and the examples mentioned, the advantage obtained by the cosmetic product described and obtained according to the present invention is evident. Petition 870250106689, dated 11 / 21 / 2025, pp. 53 / 63

Claims

1 / 4 CLAIMS 1. A non-therapeutic cosmetic product characterized in that it comprises: - at least one growth factor and at least one cytokine, secreted from a fibroblast cell culture, and - sonicated hyaluronic acid, having an average molecular weight in the range of 80 kDa to 1200 kDa; wherein said concentrate is obtainable by a process comprising the steps of: a. Providing a fibroblast cell culture in a culture medium; b. Stimulating the release of at least one growth factor and at least one cytokine into the cell culture medium of step a. to obtain a conditioned cell culture medium; c. Isolating the conditioned cell culture medium of step b. from the cell culture, to obtain an isolated conditioned cell culture medium; d. Concentrating the isolated conditioned cell culture medium of step c., wherein said step b.The method of stimulating the release of at least one growth factor and at least one cytokine in the cell culture medium is performed by subjecting said fibroblast cell culture to a nutrient deprivation step.

2. Non-therapeutic cosmetic product, according to claim 1, characterized in that said fibroblasts are isolated from a tissue sample chosen from the group consisting of skin and umbilical cord. Petition 870260000370, dated 05 / 01 / 2026, page 9 / 16 2 / 4 3. Non-therapeutic cosmetic product, according to claim 2, characterized in that said fibroblasts are isolated from said tissue sample by digestion with a protease, and subsequently with a collagenase.

4. Non-therapeutic cosmetic product, according to any one of claims 1 to 3, characterized in that said concentrate comprises a mixture of growth factors, cytokines and matrix proteins.

5. Non-therapeutic cosmetic product, according to any one of claims 1 to 4, characterized in that said concentrate comprises a growth factor selected from the group comprising: Vascular Endothelial Growth Factor (VEGF), Transforming Growth Factor β (TGF-β) and Fibroblast Growth Factors (FGFs), Platelet-Derived Growth Factor (PDGF), Granulocyte Colony-Stimulating Factor (GCSF), Keratinocyte Growth Factor (KGF), Transforming Growth Factor Beta-3 (TGF beta 3), Nerve Growth Factor Beta (NGF beta), Sirtuin 1 (SIRT 1), Sirtuin 2 (SIRT 2), Tissue Inhibitor for Metalloproteinase 1 (TIMP 1), Macrophage Colony-Stimulating Factor 1 (M-CSF or CSF 1), Stem Cell Factor (SCF), Insulin-like Growth Factor (IGF-1), Insulin-like Growth Factor 2 (IGF-2), Interleukin 10 (IL-10), and Hepatocyte Growth Factor (HGF).

6. Non-therapeutic cosmetic product, according to any one of claims 1 to 5, characterized in that said sonicated hyaluronic acid comprises fragments of sonicated hyaluronic acid having a size of Petition 870260000370, dated 05 / 01 / 2026, page 10 / 16 3 / 4 1200 to 800 kDa (5-20%), 800 to 400 kDa (30-40%), 400 to 200 kDa (30-40%) and 200 to 80 kDa (5-20%).

7. Non-therapeutic cosmetic product, according to any one of claims 1 to 6, characterized in that said cosmetic product is in the form of a cream or a serum and additionally comprises cosmetically acceptable excipients.

8. Use of the non-therapeutic cosmetic product as defined in any of claims 1 to 7, characterized by the fact that it promotes tissue regeneration.

9. Use of the non-therapeutic cosmetic product as defined in any of claims 1 to 7, characterized by being for improving skin texture.

10. Use of the non-therapeutic cosmetic product as defined in any of claims 1 to 7, characterized by being for reducing skin wrinkles.

11. Use of the non-therapeutic cosmetic product as defined in any of claims 1 to 7, characterized by the fact that it is for reducing scars.

12. Use of the non-therapeutic cosmetic product as defined in any of claims 1 to 7, characterized by being for reducing skin irritation and imperfections.

13. Product characterized by the fact that it comprises: - at least one growth factor and at least one cytokine, secreted from a fibroblast cell culture, and - hyaluronic acid, having an average molecular weight in the range of 80 kDa to 1200 kDa; Petition 870260000370, dated 05 / 01 / 2026, page 11 / 16 4 / 4 wherein said concentrate is obtainable by a process comprising the steps of: a. Providing a fibroblast cell culture in a culture medium; b. Stimulating the release of at least one growth factor and at least one cytokine into the cell culture medium of step a. to obtain a conditioned cell culture medium; c. Isolating the conditioned cell culture medium of step b. from the cell culture, to obtain an isolated conditioned cell culture medium; d. Concentrating the isolated conditioned cell culture medium of step c., wherein said step b.The method of stimulating the release of at least one growth factor and at least one cytokine in the cell culture medium is performed by subjecting said fibroblast cell culture to a nutrient deprivation step.

14. Product according to claim 13, characterized by being for use in reducing scars.

15. Product according to claim 13, characterized by being for use in the treatment of symptoms of skin irritation.

16. Product, according to claim 13, characterized by being for use in the treatment of skin irritation. Petition 870260000370, dated 05 / 01 / 2026, page 12 / 16